Filana Therapeutics (FLNA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$8.6M

Net income growth (year over year)

+80.55%

Net margin

—

Return on equity

−55.78%

EPS (trailing twelve months)

−$0.87

Book value per share

$1.32

P/E (trailing twelve months)

—

Price to book

0.58

Debt to assets

38.78%

Payout ratio

−980.20%

Dividend yield

—

Company profile

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

• How do I buy stock in Filana Therapeutics (FLNA)?

  FLNA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.